Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.40 |
| ▸ | ACACB | O00763 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22572280 | 1.00 | CNR1 (0.44) | CNR1MLYCDHDAC3HDAC4HDAC1 | |
| SCHEMBL19700718 | 0.87 | CNR1 (0.44) | CNR1HDAC3HDAC4HDAC1HDAC6 | |
| SCHEMBL21378381 | 0.87 | CNR1 (0.44) | CNR1HDAC3HDAC4HDAC1HDAC6 | |
| SCHEMBL20270226 | 0.84 | CNR1 (0.44) | CNR1MLYCDHDAC3HDAC4HDAC1 | |
| SCHEMBL20270225 | 0.84 | CNR1 (0.44) | CNR1MLYCDHDAC3HDAC4HDAC1 | |
| SCHEMBL21399933 | 0.83 | CNR1 (0.48) | CNR1HDAC3HDAC4HDAC1HDAC6 | |
| SCHEMBL21799124 | 0.81 | ACACB (0.48) | CNR1ACACBPOLB | |
| SCHEMBL20289695 | 0.81 | ACACB (0.48) | CNR1ACACBPOLB | |
| SCHEMBL20289737 | 0.81 | ACACB (0.48) | CNR1ACACBPOLB | |
| SCHEMBL22591182 | 0.80 | SMN1; SMN2 (0.42) | HDAC6MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649247-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | ELI LILLY AND COMPANY (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649247-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | ELI LILLY AND COMPANY (US) | 2023-05-16 | — | — | US | disclosed |
| EP-3763717-B1 | PYRIDO[4,3-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | LILLY CO ELI (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-3763717-B1 | PYRIDO[4,3-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | LILLY CO ELI (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20210230185-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | ELI LILLY AND COMPANY | 2021-07-29 | — | — | US | disclosed |
| US-20210230185-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | ELI LILLY AND COMPANY | 2021-07-29 | — | — | US | disclosed |
| US-20210206780-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | ELI LILLY AND COMPANY | 2021-07-08 | — | — | US | disclosed |
| US-20210206780-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | ELI LILLY AND COMPANY | 2021-07-08 | — | — | US | disclosed |
| US-11001596-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | ELI LILLY AND COMPANY (US) | 2021-05-11 | — | — | US | disclosed |
| EP-3763717-A1 | PYRIDO[4,3-D][1,3]OXAZIN-2-ONE AND PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | ELI LILLY AND CO. (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3555105-B1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | LILLY CO ELI (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-3555105-B1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | LILLY CO ELI (US) | 2020-10-28 | — | — | EP | disclosed |
| WO-2018111707-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649247-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | IDH2, IDH1, IDH3B | CNR1 4540/4885MLYCD 2026/4885HDAC3 637/4885 |
| US-20210230185-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | IDH2, IDH1, IDH3B | CNR1 4540/4885MLYCD 2026/4885HDAC3 637/4885 |
| US-20210206780-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | IDH2, IDH1, IDH3B | CNR1 4540/4885MLYCD 2026/4885HDAC3 637/4885 |
| US-11001596-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | IDH2, IDH1, IDH3B | CNR1 4540/4885MLYCD 2026/4885HDAC3 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.